Harrison School of Pharmacy

Faculty and Staff Directory


Surachat Ngorsuraches

Surachat Ngorsuraches

Associate Professor
Department: Health Outcomes Research and Policy
Auburn University
Harrison School of Pharmacy
4306a Walker Building
Auburn, AL 36849
Email: surachat@auburn.edu
Phone: 334-844-8357
Fax: 334-844-8307


Bio

Education:
  • B.Sc., Pharmacy - Prince of Songkla University (Thailand), 1992
  • M.S., Social and Administrative Pharmacy - Wisconsin, 1999
  • Ph.D., Social and Administrative Pharmacy - Wisconsin, 2002

Research Interests:
  • Pharmaceutical Economics and Policy

Surachat Ngorsuraches,Ph.D. joined the Harrison School of Pharmacy in July, 2018 as an associate professor in the Department of Health Outcomes Research and Policy. He came to HSOP after four years as an associate professor in the Department of Pharmacy Practice at South Dakota State University.

Dr. Ngorsuraches earned a degree in pharmacy from Prince of Songkla University in Thailand in 1992. He completed both his masters and doctoral degrees in social and administrative pharmacy from the School of Pharmacy at the University of Wisconsin-Madison. Since that time, he has more than 15 years of experience in teaching, conducting research, and serving the pharmacy profession.

Recently, he received a research grant from the National Multiple Sclerosis Society (NMSS) to examine patients’ treatment preferences and their willingness-to-pay for disease-modifying therapies. He has also worked on engaging patients and their family members in patient-centered multiple sclerosis research for which he received a grant award from the Patient-Centered Outcomes Research Institute (PCORI).

Dr. Ngorsuraches has been an invited speaker to numerous professional meetings and is well-published in the area of pharmaceutical economics and policy research. He has been an active member of International Society of Pharmacoeconomics and Outcomes Research (ISPOR). He chaired the ISPOR Asia consortium and served as an executive board member for the consortium. Currently, he is a member of the ISPOR Health Science Policy Council and is a member of the Healthcare Provider Council with the National Multiple Sclerosis Society.


Selected Publications
  1. Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches S. Patients’ preferences and willingness-to-pay for disease-modifying therapies. Mult Scler Relat Disord. (In press)
  2. Ngorsuraches S. 30th Anniversary of pharmaceutical care defined: Shall we reconsider its outcomes? Res Social Adm Pharm. (In press)
  3. Stenehjem DD, Au T, Ngorsuraches S, Ma J, Bauer H, Wanishayakorn T, Nelson RS, Pfeiffer CM, Schwartz J, Korytowsky B, Oderda G, Brixner D. Immuno-targeted therapy in melanoma: Patient, provider preferences, and willingness to pay at an academic cancer center. Melanoma Res. (In press)
  4. Teoh SL, Ngorsuraches S, Lai NM, Bangpan M, Chaiyakunapruk N. Factors Affecting Consumers’ Decisions on The Use of Nutraceuticals: A Systematic Review. Int J Food Sci Nutr. 2019;70:491-512.
  5. Tanvejsilp P, Taychakhoonavudh S, Chaikledkaew U, Chiyakunapruk N, Ngorsuraches S. Revisit roles of HTA on drug policy in universal health coverage in Thailand: Where are we? And What is next? Value Health Reg Issues. 2019;18:78-82.
  6. Ngorsuraches S. Value-Based Pricing of Disease-Modifying Therapies for Multiple Sclerosis: Is This Mission Possible? S D Med. 2018;71(3):134-135.
  7. Ngorsuraches S, Chaiyakunapruk N, Guo JJ, Yang B. Is It Time for Joint HTA in Asia? Opportunities and Challenges. Value Health Reg Issues. 2017;12:99-100.
  8. Ngorsuraches S, Mort JR. The Value of Subsidies of Health Plans and Cost Sharing for Prescription Drugs in Health Insurance Marketplace. Am Health Drug Benefits. 2016;9(7):368-377.
  9. Sruamsiri R, Wagner AK, Ross-Degnan D, Lu CY, Dhippayom T, Ngorsuraches S, Chaiyakunapruk N. Expanding Access to High-Cost Medicines through The E2 Access Program in Thailand: Effects on Utilization, Health Outcomes and Cost using An Interrupted Time-Series Analysis. BMJ Open. 2016;6(3):e008671. doi:10.1136/bmjopen-2015-008671.
  10. Wanishayakorn T, Sornlertlumvanich K, Ngorsuraches S. Benefit-Risk Assessment of HMG-CoA Reductase Inhibitors (Statins): A Discrete Choice Experiment. BMJ Open. 2016;6(2):e009387. doi:10.1136/bmjopen-2015-009387.
  11. Wanishayakorn T, Ngorsuraches S. Benefit-Risk Assessment of Statins (Lipid Lowering Agents): A Multi-Criteria Decision Analysis. Journal of Multi-Criteria Decision Analysis. 2016;23:28-39. doi:10.1002/mcda.1554.
  12. Nimdet K, Ngorsuraches S. Willingness to Pay per Quality-Adjusted Life year for Life-Saving Treatments in Thailand. BMJ Open. 2015;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
  13. Chancheochai S, Sakulbumrungsil R, Ngorsuraches S. Preference on Medication Therapy Management (MTM) Service: Results from Discrete Choice Experiment. The Thai Journal of Pharmaceutical Sciences. 2015;39(3):119-126.
  14. Ngorsuraches S. Methods for Benefit and Risk Assessment of Drugs. SD J Med. 2015;68(8):363, 365.
  15. Ngorsuraches S, Nawanukool K, Petcharamanee K, Poopantrakool U. Patients’ Preferences and Willingness-to-Pay for Human Papilloma Virus Vaccines in Thailand. J Pharm Policy Pract, 2015;8(1):20. doi: 10.1186/s40545-015-0040-8
  16. Ngorsuraches S, Chaiyakan K. Equitable Prices of Single-Source Drugs in Thailand. Appl Health Econ Health Policy. 2015;13(4):389-97.
  17. Nimdet K, Chaiyakunapruk N, Vichansavakul K, Ngorsuraches S. A Systematic Review of Studies Eliciting Willingness-to-Pay per Quality-Adjusted Life Year: Does It Justify CE Threshold? PLoS One. 2015;10(4):e0122760.
  18. Tanvejsilp P, Ngorsuraches S. Defining The Scope of Health Technology Assessment and Types of Health Economic Evaluation. J Med Assoc Thai. 2014;97(Suppl.5): S10-6.
  19. Li H, Ngorsuraches S. Revisit What Is Next for Pharmacoeconomics and Outcomes Research in Asia. Value Health Reg Issues. 2014;3:1-4.
  20. Ngorsuraches S, Wanishayakorn T, Tanvejsilp P, Udomaksorn S. Relative Importance of Attributes of Drug Benefit Plans: Thai Civil Servants’ Perspective. Res Social Adm Pharm. 2013;9(6):731-40.
  21. Ngorsuraches S, Meng W, Kim BY, Kulsomboon V. Drug Reimbursement Decision-making in Thailand, China, and South Korea. Value Health. 2012;15(Suppl 1):S120-5.
  22. Ngorsuraches S, Sornlertlumvanich A. Determinants of Hospital Loss in Thailand: Experience from The First Year of A Universal Coverage Health Insurance Program. Health Care Manag Sci. 2006;9:59-70.
  23. Ngorsuraches S, Saichon S. Factors Affecting Bargaining Power of Drug-Purchasing Groups in Public Hospitals in Thailand.  Songklanagarind Medical Journal. 2005;2: 93-98.
  24. Ngorsuraches S, Chaiboo B. Pharmacist Compensation Survey in Thailand.  Thai Journal of Pharmaceutical Sciences. 2004;28:125-134.
  25. Wongpoowarak P, Wanakamanee U, Panpongtham K, Trisdikoon P, Wongpoowarak W, Ngorsuraches S.  Unused Medications at Home-Reasons and Costs. Int J Pharm Pract. 2004;12:141-148.

Funded Research

Oregon Health & Science University
2018-2021
Drug effectiveness review project (DERP)
Role: Co-investigator
Total project funding awarded: $500,000

Patient-Centered Outcomes Research Institute
2017-2018
Engaging patients and their family members in patient-centered multiple sclerosis research
Role: Principle investigator
Total project funding awarded: $246,422

Sanford Health
2017
Patient engagement in the management of multiple chronic conditions
Role: Principle investigator
Total project funding awarded: $1,000

National Multiple Sclerosis Society
2016-2017
Examining the cost-escalation and patient valuation of disease-modifying therapies for multiple sclerosis
Role: Principle investigator
Total project funding awarded: $117,878.20

Bristol-Myers Squibb
2015-2016
Understanding the current and potential impact of patient interaction toward personalized treatment pathways in melanoma
Role: Co-investigator
Total project funding awarded: $5,000 (South Dakota State University subcontract)


Last Updated: July 22, 2019